Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CT 1812 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Cognition Therapeutics

    • Most Recent Events

    • 10 Feb 2021 Results presented in a Cognition Therapeutics media release.
    • 10 Feb 2021 According to a Cognition Therapeutics media release, biomarker findings from the study have been published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
    • 14 Mar 2018 According to a Cognition Therapeutics media release, results of this trial will be presented at the joint meeting of the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) and the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top